|

Goserelin 3.6 MG Clinical Trials

3 actively recruiting trials across 1 location

Also known as: ZOLADEX

Pipeline

Phase 2: 2

Top Sponsors

  • Yale University1
  • Xijing Hospital1
  • National Taiwan University Hospital1

Indications

  • Cancer3
  • Prostate Cancer2
  • HER2-negative Breast Cancer1
  • Breast Cancer1

Other2 trials

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer
N/A
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Phase 2

New Haven, Connecticut1 trial

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Yale University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.